Cargando…
The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
Epidermal Growth Factor Receptor (EGFR) antagonists were one of the first anti-cancer treatments developed targeting a Receptor Tyrosine Kinase. However, the underlying mode of action of how EGFR antagonist application can explain its clinical efficacy in different types of cancers remains largely u...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609556/ https://www.ncbi.nlm.nih.gov/pubmed/28970798 http://dx.doi.org/10.3389/fphar.2017.00575 |